Ali I. Fattom PhD

Dr. Fattom has >20 years of experience in the biopharmaceutical industry. He is an expert in vaccine development and has a track record of success in taking two programs from inception to advanced phases of clinical evaluation. Dr. Fattom was trained at the NIH in Dr. JB Robbin's laboratory. During his tenure there, he developed several vaccines including pneumococcal and Staphylococcal conjugate vaccines.

Dr. Fattom moved to Nabi Biophrmceuticals and was responsible for developing multiple vaccines and immunotherapeutics including GBS, Hepatitis B, and C immunoglobulins, Staphylococcus aureus pentavalent vaccine, and nicotine vaccine for smoking cessation. Dr. Fattom has extensive experience in evaluating vaccine adjuvants and was responsible for establishing an adjuvant and delivery evaluation program. As the VP of Research and Development at Nabi Biopharmaceuticals, Dr. Fattom was responsible for advancing vaccine programs from discovery to advanced clinical stages.

He was responsible for selecting contract manufacturing organizations for advanced phase III programs and successfully transferred manufacturing processes and analytical methods in support of commercial manufacturing of these products. In 2010, Dr. Fattom joined NanoBio as a Sr. VP of Vaccine Research and Development and ran academic collaborations. NanoBio is a small biopharmaceutical company founded in 2000 as a spin-out from the Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS) of the University of Michigan. In his current position as Sr. Vice President of Vaccine Research and Development, Dr. Fattom is responsible for developing the proprietary NanostatTM technology.

He is leading the development of a Nanoemulsion-RSV as well as Nanoemulsion-HSV whole virus-based as well as recombinant protein-based vaccines. These vaccines are optimized for intranasal (IN) or intramuscular (IM) delivery.